Featured Research

from universities, journals, and other organizations

Cancer Therapy: A Role For MAPK Inhibitors Combined With MTORC1 Inhibitors

Date:
August 21, 2008
Source:
Beth Israel Deaconess Medical Center
Summary:
Researchers identify a previously unrecognized problem faced by mTOR inhibitors when it comes to attacking cancers. Nearly a decade ago, while it was being tested as an immunosuppressive agent to prevent organ rejection in transplant patients, the drug rapamycin was also discovered to have anti-tumor properties. Since then, several rapamycin analogs known as mTOR (mammalian target of rapamycin) inhibitors have been tested in clinical trials for the treatment of various types of cancer.

Nearly a decade ago, while it was being tested as an immunosuppressive agent to prevent organ rejection in transplant patients, the drug rapamycin was also discovered to have anti-tumor properties. Since then, several rapamycin analogs known as mTOR (mammalian target of rapamycin) inhibitors have been tested in clinical trials for the treatment of various types of cancer.

But despite promising early results, mTOR inhibitors have proven less successful than originally expected.

Now research led by scientists at Beth Israel Deaconess Medical Center (BIDMC) identifies a previously unrecognized problem faced by these agents when it comes to attacking cancers. Reported in the August 21 advance on-line issue of The Journal of Clinical Investigation (JCI), the new findings show that at the same time that rapamycin analogs are halting tumor growth by inhibiting the mTOR protein complex 1 (mTORC1), they are activating the MAPK (mitogen-activated protein kinase) pathway -- thereby encouraging cancer cell survival.

"Anticancer research is aimed at understanding the molecular pathways that can be selectively targeted to halt tumor growth," explains senior author Pier Paolo Pandolfi, MD, PhD, Director of Basic Research of the Cancer Center at BIDMC and Professor of Medicine at Harvard Medical School. "We know that the mTOR pathway is activated in many cancers, and therefore, is a good target for fighting a wide array of tumors."

The mTOR pathway controls cell growth and angiogenesis through a series of mechanisms that integrate signaling from nutrients and other growth-promoting pathways. Activation of mTOR, therefore, promotes the proliferation of tumor cells, while inhibition of mTOR counters this action. However, because the mTOR signaling pathway is extremely complex, scientists have focused their efforts on identifying other agents that could be successfully combined with mTOR inhibitors to halt cancer growth.

The new findings shine a light on MAPK, a signaling pathway also known for its role in sensing growth factors to promote cell survival and proliferation.

"We analyzed tissue from human biopsies, as well as cancer cell lines and genetically engineered mouse models of cancer," explains the study's first author Arkaitz Carracedo, PhD, a postdoctoral fellow in the Pandolfi laboratory. "These experiments all pointed to the MAPK pathway."

From there, Carracedo and his coauthors went on to test a group of MAPK inhibitor agents to find out if, in combination with mTOR inhibitors, the agents would act to counter any pro-survival activity. And they did.

"This study inserts a new piece of information into the puzzle of the effects of mTORC1 inhibitors in cell signaling," says Pandolfi. "Furthermore, because there are inhibitors of MAPK pathway already approved for the treatment of cancer, it provides us with the rationale for using combinations of mTORC1 and MAPK inhibitors in attacking tumors, thereby offering cancer patients another treatment option with immediate applicability."

In addition to Pandolfi and Carracedo, study coauthors include BIDMC investigators Leonardo Salmena, Andrea Alimonti, Ainara Egia, Atsuo Sasaki, Antonella Papa, Caterina Nardella and Lewis Cantley; Memorial Sloan-Kettering Cancer Center investigator Julie Teruya-Feldstein in New York; Li Ma currently in the Whitehead Institute for Biomedical Research, Cambridge; George Thomas and Sara Kozma of the University of Cincinnati; and Federico Rojo and Jose Baselga from Vall d'Hebron University Hospital in Barcelona, Spain.

This work was supported, in part, by grants from the National Institutes of Health.


Story Source:

The above story is based on materials provided by Beth Israel Deaconess Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Beth Israel Deaconess Medical Center. "Cancer Therapy: A Role For MAPK Inhibitors Combined With MTORC1 Inhibitors." ScienceDaily. ScienceDaily, 21 August 2008. <www.sciencedaily.com/releases/2008/08/080821194721.htm>.
Beth Israel Deaconess Medical Center. (2008, August 21). Cancer Therapy: A Role For MAPK Inhibitors Combined With MTORC1 Inhibitors. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2008/08/080821194721.htm
Beth Israel Deaconess Medical Center. "Cancer Therapy: A Role For MAPK Inhibitors Combined With MTORC1 Inhibitors." ScienceDaily. www.sciencedaily.com/releases/2008/08/080821194721.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins